cd8 depleted, non-engrafting,hla mismatched unrelated donor lymphocytes
Myelodysplastic Syndromes
H. Lee Moffitt Cancer Center and Research InstituteCell therapyPhase 1/2Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 65/ 100
Competitive context
315 Active assets in the Myelodysplastic Syndromes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Sawa Ito, MD | Phase 4 | BB |
Anti-Thymoglobulin, Rabbit Peking University First Hospital | Phase 2/3 | BB |
Cytosin-Arabinosid The First Affiliated Hospital of Soochow University | Phase 4 | BB |
FILGRASTIM City of Hope Medical Center | Phase 4 | BB |
Daunorubicin OHSU Knight Cancer Institute | Phase 3 | BB |
View all 50 →
Same molecule, other indications
cd8 depleted, non-engrafting,hla mismatched unrelated donor lymphocytes is also rated in:
therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
CCC
Indicative ·
48 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →